
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **February 2020**

Commission File Number: **001-39034**

BELLUS HEALTH INC.

(Name of registrant)

**275 Armand-Frappier Blvd.
Laval, Québec
H7V 4A7
Canada**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BELLUS Health Inc.

Date: February 20, 2020

By: /s/ François Desjardins

Name: François Desjardins

Title: Vice President, Finance

Form 6-K Exhibit Index

Exhibit Number	Document Description
99.1	News Release dated February 20, 2020. BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences.



BELLUS Health Inc.
275 Armand Frappier Blvd.
Laval, Quebec, Canada H7V 4A7

BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences

LAVAL, Quebec, February 20, 2020 – BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will participate in two upcoming healthcare investor conferences.

Conference Presentation Details:

Event: SVB Leerink 9th Annual Global Healthcare Conference

Date/Time: Thursday, February 27, 2020 at 10:00 a.m. EST

Location: New York, NY

Event: Cowen and Company's 40th Annual Health Care Conference

Date/Time: Tuesday, March 3, 2020 at 8:00 a.m. EST

Location: Boston, MA

Live webcasts from the Leerink fireside chat and the Cowen conference presentation may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the events, archived webcasts and presentations will be available on the Company's website.

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.

Chronic cough, the lead indication for BLU-5937, is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life. It is estimated that approximately 26 million adults in the United States suffer from chronic cough with more than 2.6 million having refractory chronic cough lasting for more than a year. There is no specific therapy approved for refractory chronic cough and treatment options are limited.

Chronic pruritus, commonly known as chronic itch, is an irritating sensation that leads to scratching, and persists for longer than six weeks, which can be debilitating and has a significant impact on quality-of-life. It is a hallmark of many conditions, including atopic dermatitis (“AD”). It is estimated that chronic pruritus associated with AD affects more than 16.9 million adults in the United States.

FOR MORE INFORMATION, PLEASE CONTACT:Investors:

BELLUS Health

François Desjardins

Vice-President, Finance

450-680-4525

fdesjardins@bellushealth.com

Solebury Trout

Chad Rubin

646-378-2947

crubin@troutgroup.comMedia:

Solebury Trout

Joshua R. Mansbach

646-378-2964

jmansbach@troutgroup.com

SOURCE: BELLUS Health Inc.